Alnylam Pharmaceuticals
ALNY
#378
Rank
โ‚ฌ51.98 B
Marketcap
393,48ย โ‚ฌ
Share price
-1.55%
Change (1 day)
62.23%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

Alnylam Pharmaceuticals (ALNY) - Total debt

Total debt on the balance sheet as of September 2025 : โ‚ฌ1.12 Billion

According to Alnylam Pharmaceuticals 's latest financial reports the company's total debt is โ‚ฌ1.12 Billion. A companyโ€™s total debt is the sum of all current and non-current debts.

Alnylam Pharmaceuticals - Total debt on balance sheet (from 2003 to 2025)

Total debt by year

Year Total debt Change
2024-12-31โ‚ฌ1.24 B5.47%
2023-12-31โ‚ฌ1.18 B-4.06%
2022-12-31โ‚ฌ1.23 B39.73%
2021-12-31โ‚ฌ0.88 B107.88%
2020-12-31โ‚ฌ0.42 B56.24%
2019-12-31โ‚ฌ0.27 B934.23%
2018-12-31โ‚ฌ26.22 M4.88%
2017-12-31โ‚ฌ25 M-82.47%
2016-12-31โ‚ฌ0.14 B
2007-12-31โ‚ฌ4.62 M-33.15%
2006-12-31โ‚ฌ6.92 M10.91%
2005-12-31โ‚ฌ6.24 M17.6%
2004-12-31โ‚ฌ5.3 M259.52%
2003-12-31โ‚ฌ1.47 M

Total debt for similar companies or competitors

Company Total debt/th> differencediff. Country
Arrowhead Pharmaceuticals
ARWR
โ‚ฌ0.30 B-73.02%๐Ÿ‡บ๐Ÿ‡ธ USA
Regeneron Pharmaceuticals
REGN
โ‚ฌ2.32 B 106.77%๐Ÿ‡บ๐Ÿ‡ธ USA
Sarepta Therapeutics
SRPT
โ‚ฌ1.07 B-4.45%๐Ÿ‡บ๐Ÿ‡ธ USA
OPKO Health
OPK
โ‚ฌ0.33 B-69.78%๐Ÿ‡บ๐Ÿ‡ธ USA
Regulus Therapeutics
RGLS
โ‚ฌ1.2 M-99.89%๐Ÿ‡บ๐Ÿ‡ธ USA
Novartis
NVS
โ‚ฌ27.50 B 2,347.32%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
Sanofi
SNY
โ‚ฌ21.92 B 1,851.26%๐Ÿ‡ซ๐Ÿ‡ท France
Teva Pharmaceutical Industries
TEVA
โ‚ฌ14.66 B 1,204.83%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel